Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

FDA-Approved Fentanyl Drug Screening Assay to Help Identify Opioid Abuse


Illegal use of opioids in the US has been on the rise in recent years, with fentanyl being more potent and less expensive when compared to morphine and heroin.

Share this!

August 1, 2017 | by Sarah Hand, M.Sc.

For the first time, the US Food and Drug Administration (FDA) has approved a urine-based immunoassay to detect fentanyl in living patients. The SEFRIA Fentanyl Urine Enzyme Immunoassay, developed by toxicology company Immunalysis, was approved by the authority under the medical devices regulatory pathway.

While immunoassays for fentanyl detection already exist, they have largely been used in forensic testing to determine whether cause of death was due to a drug overdose. In contrast, Immunalysis’ test can be used by professionals in laboratories, hospitals and other healthcare environments to qualitatively detect fentanyl in the urine of patients.

“The availability of an FDA-cleared fentanyl immunoassay enables more reference and hospital laboratories to conduct precise qualitative screening, which is a key strategy in stemming the alarming increase in misuse and abuse of fentanyl,” said Kathy Miller, Vice President, Sales and Marketing, Immunalysis Corporation. “The SEFRIA fentanyl urine drug screening test rounds out our offering of technologically advanced assays for detecting prescription and illegal drugs of abuse by providing clinicians and toxicologists with a relevant menu of FDA-cleared opiate and opioid tests.”

Illegal use of opioids in the US has been on the rise in recent years, with fentanyl being more potent and less expensive when compared to morphine and heroin. Between 2014 and 2015, deaths attributed to synthetic opioid abuse have increased by 72 percent, according the Centers for Disease Control and Prevention.

The SEFRIA Fentanyl Urine Enzyme Immunoassay is sensitive enough to detect fentanyl levels as low as 1 ng/mL. Immunalysis is a division of Alere, a company that provides point-of-care diagnostics for the healthcare industry.

Keywords:  FDA, Opioid, Assay


Share this with your colleagues!

Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News

New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News

Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub


Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases

Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects

Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance

Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned

Copyright © 2016-2017 Honeycomb Worldwide Inc.